标题
Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance
作者
关键词
-
出版物
Viruses-Basel
Volume 7, Issue 10, Pages 5206-5224
出版商
MDPI AG
发表日期
2015-09-29
DOI
10.3390/v7102868
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance
- (2015) Inge Vliegen et al. ANTIVIRAL RESEARCH
- Structural basis for RNA replication by the hepatitis C virus polymerase
- (2015) T. C. Appleby et al. SCIENCE
- Nonnucleoside Inhibitors of Norovirus RNA Polymerase: Scaffolds for Rational Drug Design
- (2014) Auda A. Eltahla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cross-Genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders
- (2014) Auda A. Eltahla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genotypic and Phenotypic Analyses of Hepatitis C Virus Variants Observed in Clinical Studies of VX-222, a Nonnucleoside NS5B Polymerase Inhibitor
- (2014) Min Jiang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2014) Julie A. Lemm et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
- (2014) Maximilian David Schneider et al. ANTIVIRAL RESEARCH
- Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C
- (2014) Tanya L Applegate et al. ANTIVIRAL THERAPY
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection
- (2014) Adrian M. Di Bisceglie et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
- (2014) Eric F. Donaldson et al. HEPATOLOGY
- Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2014) Karen L. Rigat et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- P1303 AN INTERFERON- AND RIBAVIRIN-FREE 12-WEEK REGIMEN OF ONCE-DAILY VX-135 AND DACLATASVIR IN TREATMENT-NAÏVE PATIENTS WITH GENOTYPE 1 HCV INFECTION
- (2014) E. Gane et al. JOURNAL OF HEPATOLOGY
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
- (2014) Edward J. Gane et al. LIVER INTERNATIONAL
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Similar Prevalence of Low-Abundance Drug-Resistant Variants in Treatment-Naive Patients with Genotype 1a and 1b Hepatitis C Virus Infections as Determined by Ultradeep Pyrosequencing
- (2014) Severine Margeridon-Thermet et al. PLoS One
- Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase
- (2013) Johan Winquist et al. ANTIVIRAL RESEARCH
- In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons
- (2013) Mei Yu et al. ANTIVIRAL RESEARCH
- Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
- (2013) Edward J. Gane et al. GASTROENTEROLOGY
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
- (2013) Donald B. Smith et al. HEPATOLOGY
- JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients
- (2013) Paul J. Pockros et al. HEPATOLOGY
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients
- (2013) Heiner Wedemeyer et al. HEPATOLOGY
- New horizons in hepatitis C antiviral therapy with direct-acting antivirals
- (2013) Alessio Aghemo et al. HEPATOLOGY
- In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
- (2013) Xiao Tong et al. JOURNAL OF INFECTIOUS DISEASES
- On the History of Hepatitis C Virus Cell Culture Systems
- (2013) Volker Lohmann et al. JOURNAL OF MEDICINAL CHEMISTRY
- The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from theLos Alamosdatabank
- (2013) R. Alves et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
- (2013) Troels K H Scheel et al. NATURE MEDICINE
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
- (2013) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
- (2013) Stefania Paolucci et al. Virology Journal
- TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage
- (2012) Benoit Devogelaere et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase
- (2012) M. Fenaux et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
- (2012) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
- (2012) Jean-Michel Pawlotsky et al. ANTIVIRAL THERAPY
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- Antiviral strategies in hepatitis C virus infection
- (2012) Christoph Sarrazin et al. JOURNAL OF HEPATOLOGY
- 1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS
- (2012) F. Poordad et al. JOURNAL OF HEPATOLOGY
- 1194 CHARACTERIZATION OF VIRAL ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH BMS-791325 AND PEGYLATED INTERFERON-ALFA AND RIBAVIRIN
- (2012) D. McPhee et al. JOURNAL OF HEPATOLOGY
- 1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS
- (2012) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- 822 PRECLINICAL CHARACTERIZATION OF THE HEPATITIS C VIRUS NS5B POLYMERASE NON-NUCLEOSIDE INHIBITOR BI 207127
- (2012) P.L. Beaulieu et al. JOURNAL OF HEPATOLOGY
- Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
- (2012) Doug J. Bartels et al. JOURNAL OF VIROLOGY
- Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA
- (2012) R. T. Mosley et al. JOURNAL OF VIROLOGY
- Two Crucial Early Steps in RNA Synthesis by the Hepatitis C Virus Polymerase Involve a Dual Role of Residue 405
- (2012) N. Scrima et al. JOURNAL OF VIROLOGY
- Analysis of Hepatitis C Virus Intrahost Diversity across the Coding Region by Ultradeep Pyrosequencing
- (2012) M. Lauck et al. JOURNAL OF VIROLOGY
- Structure-Activity Relationships in the Development of Allosteric Hepatitis C Virus RNA-Dependent RNA Polymerase Inhibitors: Ten Years of Research
- (2012) Romain Haudecoeur et al. MEDICINAL RESEARCH REVIEWS
- The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
- (2012) Christy M. Hebner et al. PLoS One
- Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a
- (2012) Kelly A. Wong et al. VIROLOGY
- Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides
- (2012) Jamie J. Arnold et al. PLoS Pathogens
- Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2011) I-hung Shih et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Biochemical Study of the Comparative Inhibition of Hepatitis C Virus RNA Polymerase by VX-222 and Filibuvir
- (2011) Guanghui Yi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities
- (2011) Marina M. May et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
- (2011) Stefan Zeuzem et al. GASTROENTEROLOGY
- Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients
- (2011) Frank Wagner et al. HEPATOLOGY
- The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
- (2011) Stefan Zeuzem et al. HEPATOLOGY
- 1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL
- (2011) P. Pockros et al. JOURNAL OF HEPATOLOGY
- 445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION
- (2011) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
- (2011) JOURNAL OF HEPATOLOGY
- An Objective Assessment of Conformational Variability in Complexes of Hepatitis C Virus Polymerase with Non-Nucleoside Inhibitors
- (2011) Célia Caillet-Saguy et al. JOURNAL OF MOLECULAR BIOLOGY
- Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing
- (2011) Akihiro Nasu et al. PLoS One
- Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
- (2011) M. H. Powdrill et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New HCV therapies on the horizon
- (2010) J. Vermehren et al. CLINICAL MICROBIOLOGY AND INFECTION
- Further Insights into the Roles of GTP and the C Terminus of the Hepatitis C Virus Polymerase in the Initiation of RNA Synthesis
- (2010) Déborah Harrus et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- 2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS
- (2010) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Viral Mutation Rates
- (2010) R. Sanjuan et al. JOURNAL OF VIROLOGY
- Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase
- (2009) S. T. Shi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus
- (2009) Julie Qi Hang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- 940 SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR VCH-222 FOLLOWING SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS AND ANTIVIRAL ACTIVITY IN HCV-INFECTED INDIVIDUALS
- (2009) C. Cooper et al. JOURNAL OF HEPATOLOGY
- 1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1
- (2009) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- 955 PRECLINICAL POTENCY, PHARMACOKINETIC AND ADME CHARACTERIZATION OF ABT-333, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR
- (2009) C. Maring et al. JOURNAL OF HEPATOLOGY
- Substituted imidazopyridines as potent inhibitors of HCV replication
- (2009) Inge Vliegen et al. JOURNAL OF HEPATOLOGY
- Discovery of (R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor
- (2009) Hui Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
- (2009) J. M. Cuevas et al. JOURNAL OF VIROLOGY
- 1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside Inhibitors
- (2008) O. Nyanguile et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors
- (2008) K. J. Herlihy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796
- (2008) A. Y. M. Howe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus
- (2008) Norman M. Kneteman et al. HEPATOLOGY
- Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
- (2008) Silvana Gaudieri et al. HEPATOLOGY
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
- (2008) Thomas Kuntzen et al. HEPATOLOGY
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
- Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients
- (2008) S. Le Pogam et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More